These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. PYY3-36 as an anti-obesity drug target. Boggiano MM; Chandler PC; Oswald KD; Rodgers RJ; Blundell JE; Ishii Y; Beattie AH; Holch P; Allison DB; Schindler M; Arndt K; Rudolf K; Mark M; Schoelch C; Joost HG; Klaus S; Thöne-Reineke C; Benoit SC; Seeley RJ; Beck-Sickinger AG; Koglin N; Raun K; Madsen K; Wulff BS; Stidsen CE; Birringer M; Kreuzer OJ; Deng XY; Whitcomb DC; Halem H; Taylor J; Dong J; Datta R; Culler M; Ortmann S; Castañeda TR; Tschöp M Obes Rev; 2005 Nov; 6(4):307-22. PubMed ID: 16246216 [TBL] [Abstract][Full Text] [Related]
4. Gut hormones in the control of appetite. Murphy KG; Bloom SR Exp Physiol; 2004 Sep; 89(5):507-16. PubMed ID: 15184357 [TBL] [Abstract][Full Text] [Related]
5. Obesity research. New data on appetite-suppressing peptide challenge critics. Gura T Science; 2004 Nov; 306(5701):1453-4. PubMed ID: 15567820 [No Abstract] [Full Text] [Related]
7. Control of food intake and energy expenditure by amylin-therapeutic implications. Lutz TA Int J Obes (Lond); 2009 Apr; 33 Suppl 1():S24-7. PubMed ID: 19363503 [TBL] [Abstract][Full Text] [Related]
8. Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass. Fenske WK; Bueter M; Miras AD; Ghatei MA; Bloom SR; le Roux CW Int J Obes (Lond); 2012 Mar; 36(3):379-84. PubMed ID: 21694700 [TBL] [Abstract][Full Text] [Related]
13. Neuro-hormonal control of food intake: basic mechanisms and clinical implications. Konturek PC; Konturek JW; Cześnikiewicz-Guzik M; Brzozowski T; Sito E; Konturek SJ J Physiol Pharmacol; 2005 Dec; 56 Suppl 6():5-25. PubMed ID: 16340035 [TBL] [Abstract][Full Text] [Related]
14. 5-HT(2C) receptor agonists and the control of appetite. Halford JC; Harrold JA Handb Exp Pharmacol; 2012; (209):349-56. PubMed ID: 22249823 [TBL] [Abstract][Full Text] [Related]
16. Neuropeptide-Y Y2-receptor agonist, PYY3-36 promotes non-rapid eye movement sleep in rat. Akanmu MA; Ukponmwan OE; Katayama Y; Honda K Neurosci Res; 2006 Mar; 54(3):165-70. PubMed ID: 16378653 [TBL] [Abstract][Full Text] [Related]
17. Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats. Nadkarni PP; Costanzo RM; Sakagami M Diabetes Obes Metab; 2011 May; 13(5):408-17. PubMed ID: 21226821 [TBL] [Abstract][Full Text] [Related]
18. News in gut-brain communication: a role of peptide YY (PYY) in human obesity and following bariatric surgery? Hanusch-Enserer U; Roden M Eur J Clin Invest; 2005 Jul; 35(7):425-30. PubMed ID: 16008543 [TBL] [Abstract][Full Text] [Related]
19. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Abbott CR; Small CJ; Kennedy AR; Neary NM; Sajedi A; Ghatei MA; Bloom SR Brain Res; 2005 May; 1043(1-2):139-44. PubMed ID: 15862527 [TBL] [Abstract][Full Text] [Related]
20. Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour. Scott V; Kimura N; Stark JA; Luckman SM J Neuroendocrinol; 2005 Jul; 17(7):452-7. PubMed ID: 15946163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]